NCT03192501 2024-06-25
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
Second Affiliated Hospital of Guangzhou Medical University
Recruiting
Clinical Trials
73 trialsNCT03076164 2024-04-02
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05081674 2023-10-11
BLISS
Hospital Israelita Albert Einstein
Phase 2 Completed
NCT01859026 2023-01-19
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00871923 2021-09-16
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01302808 2021-01-20
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01556191 2021-01-08
LADIE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT00888511 2020-11-27
TARLAL
Odense University Hospital
Phase 2 Completed
NCT00835471 2020-09-29
NVALT10
Dutch Society of Physicians for Pulmonology and Tuberculosis
Phase 2 Completed
NCT00547105 2020-08-21
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00278148 2020-07-20
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00411632 2020-01-29
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02745691 2019-12-13
Psychometric Properties of the EORTC QLQ-LC29
University Hospital Regensburg
Completed
NCT00563784 2019-11-20
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04145570 2019-10-30
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
Quadras Scientific Solutions
Phase 4 Completed
NCT00354549 2019-05-15
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
Swiss Cancer Institute
Phase 2 Completed
NCT01116219 2019-05-15
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Swiss Cancer Institute
Phase 2 Completed
NCT02889692 2019-04-11
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
Phase 3 Completed
NCT00100854 2019-03-05
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Translational Oncology Research International
Phase 2 Completed
NCT02155465 2019-01-16
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00287989 2018-12-06
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00390429 2018-12-06
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Phase 1/2 Completed
NCT00043823 2018-11-07
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01407822 2018-09-11
EMERGING
Guangdong Association of Clinical Trials
Phase 2/3 Unknown
NCT00462995 2018-02-23
SELECT
University Health Network, Toronto
Phase 2 Completed
NCT00553462 2018-01-31
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00577707 2018-01-10
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01344824 2017-10-30
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00410059 2017-08-02
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02178397 2017-07-17
FLARE
Centre Francois Baclesse
Phase 3 Terminated
NCT00280150 2017-06-19
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00550537 2017-06-08
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00408499 2017-05-08
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
University of California, Davis
Phase 1/2 Completed
NCT00283244 2017-04-24
Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00473083 2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2 Completed
NCT01024413 2017-03-01
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Chinese Society of Lung Cancer
Phase 3 Completed
NCT02795884 2016-12-30
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Yonsei University
Phase 3 Withdrawn
NCT00826449 2016-06-28
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01047059 2016-05-20
MIMEB
University of Cologne
Phase 2 Completed
NCT00063258 2016-05-09
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02704767 2016-03-10
Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma
First Affiliated Hospital of Kunming Medical University
Phase 2 Unknown
NCT00367601 2016-02-11
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01402089 2016-02-02
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Cantonal Hospital of St. Gallen
Phase 4 Completed
NCT01027598 2016-01-29
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02625168 2015-12-09
Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
The University of Hong Kong
Phase 2 Completed
NCT00988169 2015-11-20
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01189435 2015-11-18
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00660816 2015-10-12
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02321293 2015-09-02
CURCUMIN
Lady Davis Institute
Phase 1 Unknown